Inactive Instrument

Protalex, Inc.

PRTX

US7436422098

Biotechnology & Medical Research

Protalex Plans To Raise Funds

October 12, 2018 at 05:00 am

Protalex, Inc. (OTCPK:PRTX) continues to actively seek sources of financing to fund continuing operations and development programs. To raise additional capital, it may sell equity or debt securities.

Latest news about Protalex, Inc.

Protalex, Inc. Announces Management Resignations	30/11/18	CI
Protalex Plans To Raise Funds	12/10/18	CI
Protalex, Inc. Announces Data Highlighting Results from European Phase 1b of PRTX-100 in Patients with Immune Thrombocytopenia	15/06/18	CI
Protalex, Inc. Announces Lead Drug Candidate PRTX-100 Reduces Disease Activity in Mouse Model of Myasthenia Gravis	12/06/18	CI
Protalex, Inc. Initiates Fourth Cohort Dosing of Phase 1/2 Study of PRTX-100 in Immune Thrombocytopenia	09/04/18	CI
Protalex, Inc. announced that it has received $1.43 million in funding	27/02/18	CI
Protalex Doses First Patient in Final and Highest Dose Cohort of European Phase 1b Study of PRTX-100 in Immune Thrombocytopenia	18/01/18	CI
Protalex Doses First Patient in Fourth Cohort of European Phase 1b Study of PRTX-100 in ITP	13/11/17	CI
Protalex, Inc. Announces Preclinical Data of Haematology Supporting the Potential of PRTX-100 to Treat Immune Thrombocytopenia	26/10/17	CI
Protalex Doses First Patient in Third Cohort of European Phase 1b Study of PRTX-100 in ITP	29/08/17	CI
Protalex, Inc. Announces Completion of Escalating the U.S. Phase 1/2 Study of PRTX-100 in Adults	01/08/17	CI
Protalex, Inc. Provides Update on US and EU Studies of PRTX-100 to Treat Immune Thrombocytopenia	21/02/17	CI
Protalex, Inc. Enters Amendment to Credit Facility	07/07/16	CI
Protalex Inc. Receives Positive Interim Review from Independent Safety Monitoring Committee in its European Phase 1B Study of PRTX-100 to Treat Immune Thrombocytopenia	02/05/16	CI
Protalex Announces Preliminary Findings from Phase I/II Continuation Trial of PRTX-100 in Active Rheumatoid Arthritis Patients	25/04/16	CI
Protalex Announces Interim Review of its U.S. Phase 1/2 Study of PRTX-100 for Immune Thrombocytopenia	29/02/16	CI
Protalex, Inc. Announces First Patient Dosed in European Phase Ib Study of PRTX-100 for Immune Thrombocytopenia	07/01/16	CI
Protalex Announces Regulatory Approval to Initiate Phase Ib Trial of PRTX-100 to Treat Immune Thrombocytopenia in France	05/10/15	CI
Protalex, Inc. to Initiate Enrollment of U.S. Phase I/II Trial of PRTX-100 to Treat Immune Thrombocytopenia	03/09/15	CI
Protalex, Inc. Auditor Raises 'Going Concern' Doubt	30/07/15	CI
Protalex Announces Findings from Final Cohort of U.S. Phase 1b Trial of Prtx-100 in Active Rheumatoid Arthritis Patients	16/04/15	CI
Protalex, Inc. Initiates Enrollment of Phase I/Ii Continuation Trial of PRTX-100 in Active Rheumatoid Arthritis Patients	12/03/15	CI
Protalex Inc. Announces Data from Phase 1b Trial of PRTX 100 in Patients with Active Rheumatoid Arthritis	18/11/14	CI
Protalex Inc. Enters New Credit Facility Agreement with Niobe Ventures, LLC	07/11/14	CI
Protalex Announces Results from Cohorts 1-4	15/05/14	CI

Protalex, Inc. is a clinical-stage company. The Company is focused on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Immune Thrombocytopenia (ITP). The Company's lead product candidate, PRTX-100, is a formulation of the Staphylococcal bacterial protein known as Protein A, which modifies aspects of the human immune system. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. The Company's pre-clinical studies demonstrated that low doses of PRTX-100 have potent therapeutic effects in certain models of immune-mediated inflammatory diseases. Both the PRTX-100-103 and the PRTX-100-104 studies demonstrated that PRTX-100 is safe and well tolerated at all dose levels.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	114B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
ARGENX SE	+0.41%	22.28B
BIONTECH SE	-11.90%	22.41B
GENMAB A/S	-5.99%	19.07B
WUXI APPTEC CO., LTD.	-37.36%	18B
BEIGENE, LTD.	-5.17%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.28B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.55B

Bio Therapeutic Drugs

Protalex, Inc.

Equities

PRTX

US7436422098

Biotechnology & Medical Research

Protalex Plans To Raise Funds

Latest news about Protalex, Inc.

Chart Protalex, Inc.

Company Profile

Sector Bio Therapeutic Drugs